Sorafenib 200mg Tablets$152.00
1–9 boxes
$152.00 each
10–24 boxes
8% off
25+ boxes
10% off
Sorafenib 200mg Tablets
SKU GME1102Oncology Care
Product Introduction
Sorafenib 200mg is a targeted treatment for selected liver, kidney and differentiated thyroid cancers. It is used when the disease setting calls for systemic treatment, including certain tumours that cannot be removed surgically or no longer respond to radioactive iodine.
How to use
Take the tablets on an empty stomach, at least one hour before or two hours after food, usually in two daily doses. Swallow them with water. If a dose is missed, skip it and take the next scheduled dose rather than doubling the amount.
How it works
Sorafenib blocks RAF signalling and several receptors involved in tumour blood-vessel growth, including VEGF receptors. This interferes with cancer-cell growth and reduces the vascular support available to the tumour.
Side effects
Hand-foot skin reaction, diarrhoea, fatigue, appetite loss, weight loss, rash and hair thinning are common. High blood pressure, bleeding, heart ischaemia and liver injury can be serious. Chest pain or substantial bleeding requires emergency care.
Important information
Blood pressure is checked frequently during the first weeks, with ongoing liver and other laboratory monitoring. Report painful palms or soles early so skin care and treatment adjustments can limit severity. Surgery needs a planned interruption because wound healing may be affected.
Uses
- Unresectable hepatocellular carcinoma
- advanced renal-cell carcinoma
- progressive differentiated thyroid cancer that is refractory to radioactive iodine.
Benefits
Sorafenib can slow growth and progression in responsive cancers through both tumour-cell and blood-vessel pathways. Scans and disease-specific tests establish whether this control is continuing.
What can I do about early soreness on my palms or soles?
Reduce friction and pressure, use an emollient and report tenderness or blistering promptly. Early treatment can prevent a mild hand-foot reaction from interfering with walking or daily tasks.
Does this treat every type of thyroid cancer?
No. Its established thyroid-cancer role is differentiated disease that is progressive and radioactive-iodine refractory, not all thyroid tumour types.
Why is blood pressure checked when my treatment is for cancer?
Blocking VEGF signalling can raise blood pressure, sometimes early in treatment. Monitoring identifies this before headache, visual symptoms or cardiovascular complications develop.
Should I take an extra dose after vomiting?
Do not replace a vomited dose with extra tablets. Resume the next scheduled dose, and report repeated vomiting because dehydration and poor medicine intake can affect treatment.
RAF: protein in a cell-growth signalling pathway. VEGF receptor: signalling target involved in blood-vessel formation. Radioiodine-refractory: not responding adequately to radioactive iodine. Hand-foot reaction: painful skin change on palms or soles. Systemic treatment: therapy acting throughout the body.; AR: Sorafenib 200mg أقراص; FR: Sorafenib 200mg comprimés; PT: Sorafenib 200mg comprimidos; ES: Sorafenib 200mg comprimidos; RU: Sorafenib 200mg таблетки; ID: Sorafenib 200mg tablet; VI: Sorafenib 200mg viên nén; MS: Sorafenib 200mg tablet; TL: Sorafenib 200mg tableta; ZH-SG: Sorafenib 200mg 片剂